menu search

AGIO / Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same. Read More
Posted: Nov 3 2023, 12:47
Author Name: Zacks Investment Research
Views: 100964

AGIO News  

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

By Zacks Investment Research
November 3, 2023

Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales

Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same. more_horizontal

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

By GlobeNewsWire
November 2, 2023

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease more_horizontal

Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study

By Seeking Alpha
August 17, 2023

Agios Pharmaceuticals: Positive Phase 2 Results In Sickle Cell Study

Agios Pharmaceuticals is a biotech company focused on developing medicines for cancer and rare genetic diseases. The company's financials show growth, more_horizontal

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

By Zacks Investment Research
August 4, 2023

Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line

Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate. more_horizontal

Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 3, 2023

Agios Pharmaceuticals, Inc. (AGIO) Q2 2023 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2023 Results Conference Call August 3, 2023 8:00 AM ET Company Participants Christopher Taylor - Vice Pr more_horizontal

Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet

By Zacks Investment Research
July 17, 2023

Wall Street Analysts Think Agios Pharmaceuticals (AGIO) Could Surge 42.06%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 42.1% in Agios Pharmaceuticals (AGIO). While the effectivenes more_horizontal

Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?

By Zacks Investment Research
June 28, 2023

Are Medical Stocks Lagging Agios Pharmaceuticals (AGIO) This Year?

Here is how Agios Pharmaceuticals (AGIO) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year. more_horizontal

Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint

By Zacks Investment Research
June 27, 2023

Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint

Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed wi more_horizontal


Search within

Pages Search Results: